According to the North China Pharmaceutical announcement, the company received the “Drug Registration Certificate” for injectable piperacillin sodium tazobactam sodium/sodium chloride injections approved by the State Drug Administration. It is the first company to be approved in China and is considered to have passed the consistent evaluation of the quality and efficacy of generic drugs. This product is a four-class chemical injection, suitable for the treatment of moderate to severe infections, with a total R&D investment of 26.372,500 yuan. This approval enriches the company's anti-infective product pipeline, complements the dosage form with existing powder injections, and there is uncertainty about product sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.